[go: up one dir, main page]

USRE32535E - Process for the preparation of α-6-deoxytetracyclines - Google Patents

Process for the preparation of α-6-deoxytetracyclines Download PDF

Info

Publication number
USRE32535E
USRE32535E US06/858,660 US85866086A USRE32535E US RE32535 E USRE32535 E US RE32535E US 85866086 A US85866086 A US 85866086A US RE32535 E USRE32535 E US RE32535E
Authority
US
United States
Prior art keywords
process according
catalyst
salt
reaction mixture
tertiary phosphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/858,660
Inventor
Ivan Villax
Philip R. Page
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plurichemie Anstalt
Original Assignee
Plurichemie Anstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PT198274303A external-priority patent/PT74303B/en
Priority claimed from PT198276061A external-priority patent/PT76061A/en
Application filed by Plurichemie Anstalt filed Critical Plurichemie Anstalt
Priority to US06/858,660 priority Critical patent/USRE32535E/en
Application granted granted Critical
Publication of USRE32535E publication Critical patent/USRE32535E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60—Reduction reactions, e.g. hydrogenation
    • B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/822—Rhodium

Definitions

  • the present invention refers to a new improved process for the preparation of ⁇ -6-deoxytetracyclines, more particularly to the stereospecific hydrogenation of the 6-methylene group of 6-deoxy-6-demethyl-6-methylene-5-hydroxytetracycline and of its 11a-halo analogue, and to the subsequent recovery of pure doxycycline as p-toluenesulphonate directly from the reaction mixture in a nearly stoichiometric yield.
  • Another feature of the present invention is that the amount of catalyst, expressed as metal, more specifically as rhodium, necessary to perform the hydrogenation of the exocyclic methylene group is considerably reduced in comparison to the teaching of the prior art, and therefore the process is very economical.
  • U.S. Pat No. 3,954,862 (first filed in 1973) describes the hydrogenation of 6-deoxy-6-demethyl-6-methylenetracyclines in the presence of rhodium metal, a tertiary phosphine and a promoter selected from strong acid or stannous chloride.
  • this process prepares the catalyst, described in U.S. Pat. No. 4,207,258, in the reaction mixture, starting from rhodium metal and strong acid or stannous chloride, instead of the equivalent rhodium chloride.
  • Doxycycline is prepared by hydrogenation of 6-methylene-5-hydroxytetracycline, using cobalt carbonyl, triphenylphosphine and hydrochloric acid in U.S. Pat. No. 3,907,890 (filed in 1974).
  • the present invention relates to the use of new homogeneous rhodium catalysts, the preparation of which are described in our co-pending patent application Ser. No. 458,068 filed on even date herewith.
  • These new catalysts are obtained by reacting a rhodium salt, preferably rhodium chloride, a tertiary phosphine, preferably triphenylphosphine, and an eventually substituted hydrazine, preferably hydrazine hydrate, in a reaction inert solvent.
  • these catalysts can be prepared by reacting a known complex of rhodium and of a tertiary phosphine with a hydrazine in a reaction inert solvent.
  • These nitrogen containing new rhodium catalysts are stereospecific, yielding nearly exclusively the ⁇ -isomer.
  • the present invention concerns the preparation of ⁇ -6-deoxytetracyclines by hydrogenating a compound of the formula: ##STR1## in which R 1 is hydrogen or hydroxy group and R 2 is hydrogen or chlorine, in a reaction inert solvent, in the presence of a tertiary phosphine-hydrazinochlororhodium complex as catalyst.
  • the pressure is not critical; it can be from atmospheric pressure upwards, however the preferred pressure range is from 4 to 10 kg/cm 2 .
  • the hydrogenation is carried out preferably at a temperature range from about 60° C. to 90° C. At lower temperatures, the reaction is too slow and above 100° C. decomposition takes place.
  • the reaction time is dependent on the amount of catalyst used and type of hydrogenation. A satisfactory reaction time is from about 3 to 10 hours, but satisfactory results and high yields can be obtained even after 16 hours of hydrogenation.
  • the starting material is added in the form of an acid addition salt, such as hydrochloride, p-toluenesulphonate, but other acid addition salts can be used provided that the acid is not a catalyst poison.
  • an acid addition salt such as hydrochloride, p-toluenesulphonate, but other acid addition salts can be used provided that the acid is not a catalyst poison.
  • the 6-methylene-5-oxytetracycline (methacycline; MOT) can be prepared by any of the known processes but should not contain impurities which may act as catalyst poisons.
  • the hydrogenation is stopped when the rate of consumption of hydrogen drops drastically.
  • the reaction mixture once the hydrogenation is completed, containing nearly exclusively the ⁇ -isomer, does not contain unreacted starting material or only traces; the amount of by-products or degradation products is negligible and the ⁇ -isomer is less than 1%, usually it is around 0.1%.
  • the purity of the reaction mixture thus obtained is such that the doxycycline can be crystallised directly from said reaction mixture by adding p-toluenesulphonic acid in excess, on condition that the solvent in the reaction medium is a non-solvent for the p-toluenesulphonate salt of doxycycline thus formed; such a solvent is preferably methanol.
  • the purity so obtained is superior to 99% calculated on the dry basis.
  • the doxycycline p-toluenesulphonate can subsequently be transformed directly into the hydrochloride hemiethanolate hemihydrate by conventional processes with a yield near to stoichiometric.
  • Another inventive feature of the present invention is that the amount of rhodium necessary to achieve complete hydrogenation is drastically reduced in comparison to the amount used in the prior art processes.
  • Table I compares the amount of catalyst, yields and purity of the best examples of prior art processes with those of the present invention.
  • the present invention is also applicable to transform 11a-halo-6-deoxy-6-demethyl-6-methylenetetracyclines into ⁇ -6-deoxytetracyclines in one reaction by dehalogenating at 11a- and simultaneously reducing the 6-methylene group.
  • the yields and purity are very high and the
  • Chloromethacycline prepared according to U.S. Pat. No. 3,849,491, is an eminently suitable starting material in the present invention.
  • an 11a-halo-6-deoxy-6-demethyl-6-methylenetetracycline preferably 11a-chloro-6-deoxy-6-demethyl-6-methylene-oxytetracycline p-toluenesulphonate
  • a tertiary phosphinehydrazino-chlororhodium catalyst and an additional amount of tertiary phosphine are added under stirring and hydrogenated subsequently at about 60° C. to 90° C. at a pressure between 4 and 10 kg/cm 2 until the rate of consumption of hydrogen drops drastically.
  • the reaction mixture is cooled down to about 45° C.
  • Table II gives a comparison of the present invention with the state of art in transforming 11a-chloro-6-deoxy-6-demethyl-6-methylene-5-oxytetracycline into ⁇ -6-deoxyoxytetracycline.
  • These new catalysts can be prepared either from a rhodium salt or from the already known tertiary phosphine rhodium complexes.
  • rhodium trichloride trihydrate (1 mole), a tertiary phosphine (1 to 2.5 moles) and an excess of hydrazine (up to 10 moles) are reacted, eventually by heating or refluxing them in a reaction inert solvent, such as a lower dialylketone, lower alcohol, tetrahydrofuran, dioxan or dimethylformamide, and the formed catalyst is then filtered off if it is insoluble in the reaction mixture or precipitated by adding a non-solvent, such as isopropylether, then filtered and dried.
  • a reaction inert solvent such as a lower dialylketone, lower alcohol, tetrahydrofuran, dioxan or dimethylformamide
  • Rhodium chloride trihydrate reacts with an excess of hydrazine hydrate, yielding a yellow compound which does not catalyse the hydrogenation of 6-methylene-oxytetracycline if triphenylphosphine is not added to the reaction mixture. In the presence of triphenylphosphine, however, a good quality ⁇ -6-deoxyoxytetracycline is obtained in high yield.
  • a tertiary phosphine rhodium complex (1 mole) can be reacted with an excess of hydrazine, substituted or not, the preferred catalyst being prepared by reacting tris(triphenylphosphine)chlororhodium (I) (1 mole) with an excess of hydrazine hydrate (3 moles) by stirring at room temperature in methanol. When the reaction mixture turns yellow, it is stirred for a few more minutes and it can be used either without isolation or it is filtered, washed and dried.
  • stationary phase 100 ml of a solution of 0.1M citric acid and 40 ml of 0.2M anhydrous disodium phosphate were mixed to make a buffer with pH 3.5; mobile phase: nitromethane:chloroform:pyridine-20:10:3).
  • Example 1 was repeated but 15 mg of the catalyst was added instead of 25 mg.
  • the ⁇ -6-deoxyoxytetracycline p-toluenesulphonate weighed 8.57 g. Yield 90%. It contained 0.45% of the ⁇ -isomer and traces of starting material.
  • Example 5 25 mg of the catalyst as obtained in Example 5 in 20 ml of methanol was added to a stainless steel hydrogenator containing 7.38 g of 6-methylene-5-hydroxytetracycline hydrochloride in 40 ml of methanol. The hydrogenation and isolation were carried out as described in Example 1.
  • the ⁇ -6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.17 g and had the following analytical values: humidity 2.18% by Karl-Fisher, yield 84.1% and purity 99.2%, both on anhydrous basis.
  • Example 1 was repeated using 25 mg of the catalyst obtained hereinabove.
  • the ⁇ -6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.33 g. Yield 87.6%. It did not contain any starting material or ⁇ -isomer by circular paper chromatography.
  • Example 8 was repeated but 68 mg of triphenylphosphine was also added to the reaction mixture prior to hydrogenation.
  • the ⁇ -6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 5.36 g. Yield 83.3%. It contained traces of the ⁇ -isomer.
  • the second crop as sulphosalicylate weighed 0.7 g and contained about 4% of the ⁇ -isomer.
  • Example 10 was repeated but no triphenylphosphine was added to the hydrogenation reaction mixture. There was no consumption of hydrogen and the 6-methylene-5-hydroxytetracycline remained unchanged.
  • ⁇ -isomer The content of ⁇ -isomer was 0.3% and no starting material was present by h.p.l.c. (Column: ⁇ Bondapak "Waters" CN--ref. No. PN 84042 S/N; solvent: 80% of tetrahydrofuran, 20% of a mixture containing 80% of water, 20% acetic acid in 0.001M EDTA; flow rate: 2.5 ml/min.; detection: U.V. 268 nm; 1.0 AUFS; chart: 5 mm/min.).
  • Example 12 (B) was repeated using 25 mg of the triphenylphosphine-hydrazino-chlororhodium complex obtained hereinabove.
  • the ⁇ -6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.02 g. Yield 84.4%. No ⁇ -isomer or starting material were detectable by circular paper chromatography.
  • Example 12 (B) was repeated using 25 mg of the catalyst obtained hereinabove.
  • the ⁇ -6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.04 g. Yield 84.6%. No ⁇ -isomer and no starting material were detectable by circular paper chromatography.
  • the ⁇ -6-deoxyoxytetracycline p-toluenesulphonate thus formed weighed 8.16 g. Yield 85.9%. No ⁇ -isomer was detectable and slight traces of starting material were present in circular paper chromatography.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Abstract

An improved process for the preparation of α-6-deoxytetracyclines and more particularly to the stereo specific hydrogenation of the 6-methylene group of 6-deoxy-6-demethyl-6-methylene-5-hydroxytetracyline and of its 11α-halo-analog, is described in which the catalyst is the reaction product of a rhodium salt or a complex with a hydrazine or salt thereof.

Description

The present invention refers to a new improved process for the preparation of α-6-deoxytetracyclines, more particularly to the stereospecific hydrogenation of the 6-methylene group of 6-deoxy-6-demethyl-6-methylene-5-hydroxytetracycline and of its 11a-halo analogue, and to the subsequent recovery of pure doxycycline as p-toluenesulphonate directly from the reaction mixture in a nearly stoichiometric yield.
Another feature of the present invention is that the amount of catalyst, expressed as metal, more specifically as rhodium, necessary to perform the hydrogenation of the exocyclic methylene group is considerably reduced in comparison to the teaching of the prior art, and therefore the process is very economical.
The α-isomer of 6-deoxy-5-hydroxytetracycline (doxycycline) was first isolated in pure form and described in U.S. Pat. No. 3,200,149, applied for in 1960. Subsequently, a considerable number of patents referred to improved processes for preparing doxycycline. However, none of them was stereospecific and the yields obtained lay between 8 and 64% until the discovery of the first homogeneous hydrogenation process.
U.S. Pat. No. 4,207,258 (Italian priority 1972) describes such homogeneous hydrogenation of 6-deoxy-6-demethyl-6-methylenetetracyclines, using a complex of rhodium with tertiary phosphine, arsine and stibine ligands with predominant formation of the α-isomer.
U.S. Pat. No. 3,962,331 (Italian priority 1973) extends the above process to the simultaneous reductive dehalogenation and hydrogenation of the exocyclic methylene group of 11a-halo-6-deoxy-6-demethyl-6-methylenetetracycline. Essentially the same processes, equivalent to the above two, are described in French Pat. No. 2,216,268 (U.S. priority 1973).
U.S. Pat No. 3,954,862 (first filed in 1973) describes the hydrogenation of 6-deoxy-6-demethyl-6-methylenetracyclines in the presence of rhodium metal, a tertiary phosphine and a promoter selected from strong acid or stannous chloride. Thus, this process prepares the catalyst, described in U.S. Pat. No. 4,207,258, in the reaction mixture, starting from rhodium metal and strong acid or stannous chloride, instead of the equivalent rhodium chloride.
Doxycycline is prepared by hydrogenation of 6-methylene-5-hydroxytetracycline, using cobalt carbonyl, triphenylphosphine and hydrochloric acid in U.S. Pat. No. 3,907,890 (filed in 1974).
U.S. Pat. No. 4,001,321 (filed in 1975) employs dicarboxylato (triphenylphosphine) rhodium (II) or dicarboxylato (substituted triphenylphophine) rhodium (II) to produce doxycycline by hydrogenation.
U.S. Pat. No. 3,962,131 (filed in 1975) describes the preparation of a new catalyst by reacting rhodium trichloride, sodium acetate, followed by reaction with triphenylphosphine and the hydrogenation of 6-deoxy-6-demethyl-6-methylene-5-hydroxytetracycline in its presence.
The present invention relates to the use of new homogeneous rhodium catalysts, the preparation of which are described in our co-pending patent application Ser. No. 458,068 filed on even date herewith.
These new catalysts are obtained by reacting a rhodium salt, preferably rhodium chloride, a tertiary phosphine, preferably triphenylphosphine, and an eventually substituted hydrazine, preferably hydrazine hydrate, in a reaction inert solvent. Alternatively, these catalysts can be prepared by reacting a known complex of rhodium and of a tertiary phosphine with a hydrazine in a reaction inert solvent. These nitrogen containing new rhodium catalysts are stereospecific, yielding nearly exclusively the α-isomer.
Thus, the present invention concerns the preparation of α-6-deoxytetracyclines by hydrogenating a compound of the formula: ##STR1## in which R1 is hydrogen or hydroxy group and R2 is hydrogen or chlorine, in a reaction inert solvent, in the presence of a tertiary phosphine-hydrazinochlororhodium complex as catalyst.
The pressure is not critical; it can be from atmospheric pressure upwards, however the preferred pressure range is from 4 to 10 kg/cm2. The hydrogenation is carried out preferably at a temperature range from about 60° C. to 90° C. At lower temperatures, the reaction is too slow and above 100° C. decomposition takes place.
The reaction time is dependent on the amount of catalyst used and type of hydrogenation. A satisfactory reaction time is from about 3 to 10 hours, but satisfactory results and high yields can be obtained even after 16 hours of hydrogenation.
The starting material is added in the form of an acid addition salt, such as hydrochloride, p-toluenesulphonate, but other acid addition salts can be used provided that the acid is not a catalyst poison.
The 6-methylene-5-oxytetracycline (methacycline; MOT) can be prepared by any of the known processes but should not contain impurities which may act as catalyst poisons.
The hydrogenation is stopped when the rate of consumption of hydrogen drops drastically. The reaction mixture, once the hydrogenation is completed, containing nearly exclusively the α-isomer, does not contain unreacted starting material or only traces; the amount of by-products or degradation products is negligible and the β-isomer is less than 1%, usually it is around 0.1%.
It has been observed that the addition of a small amount, in the order of 0.01 to 0.06 mole/mole of a tertiary phosphine (preferably the same one contained in the catalyst used) to the reaction mixture, prior to starting hydrogenation, will accelerate the rate of hydrogen consumption, facilitate completion of the reaction and increase the yield up to 100%. The amount of the tertiary phosphine is critical and an excess above the amount indicated will reduce the yield. The optimum amount of additional tertiary phosphine can easily be determined for a given batch of catalyst by running a few experiments.
The purity of the reaction mixture thus obtained is such that the doxycycline can be crystallised directly from said reaction mixture by adding p-toluenesulphonic acid in excess, on condition that the solvent in the reaction medium is a non-solvent for the p-toluenesulphonate salt of doxycycline thus formed; such a solvent is preferably methanol. The purity so obtained is superior to 99% calculated on the dry basis.
The doxycycline p-toluenesulphonate can subsequently be transformed directly into the hydrochloride hemiethanolate hemihydrate by conventional processes with a yield near to stoichiometric.
Another inventive feature of the present invention is that the amount of rhodium necessary to achieve complete hydrogenation is drastically reduced in comparison to the amount used in the prior art processes.
Table I compares the amount of catalyst, yields and purity of the best examples of prior art processes with those of the present invention.
This table shows that the present invention not only surpasses in yield and purity the prior art processes but also the amount of rhodium necessary to hydrogenate a given amount of 6-methylene-oxytetracycline is reduced by 4 to 1000 times in relation to the prior art teaching. As rhodium is an extremely expensive noble metal, this reduction represents an important unexpected improvement, which, together with the nearly stoichiometric yield, results in a considerable reduction of manufacturing costs.
Furthermore, it has been found that the present invention is also applicable to transform 11a-halo-6-deoxy-6-demethyl-6-methylenetetracyclines into α-6-deoxytetracyclines in one reaction by dehalogenating at 11a- and simultaneously reducing the 6-methylene group. The yields and purity are very high and the
                                  TABLE I                                 
__________________________________________________________________________
             Amount of rho-                                               
                     Stoichiome-                                          
             dium used per                                                
                     tric yield                                           
                           Content as     Purity of iso-                  
Patent       kg. 6-methyl-                                                
                     of isolated    Starting                              
                                          lated product                   
No.     Example                                                           
             ene-oxyic. HCl                                               
                     product %                                            
                           α-6%                                     
                               β-6%                                  
                                    material %                            
                                          %                               
__________________________________________________________________________
U.S. Pat. No.                                                             
        2    1954.Iadd.0 .Iaddend.mg.                                     
                     75.0  N.S.                                           
                               N.S. N.S.  99.3.sup.(2)                    
4,207,258                                                                 
French Patent                                                             
        3    21252 mg.                                                    
                     90.6  N.S.                                           
                               N.S. N.S.  N.S.                            
2216268 5    2125 mg.                                                     
                     89.2  N.S.                                           
                               0.6  0     N.S.                            
        .sup.  9.sup.(5)                                                  
             556 mg. 78.5  78.4                                           
                               0.8   5.2  78.4                            
U.S. Pat No.                                                              
        3    1962 mg.                                                     
                     80.0   81.0*                                         
                               1.6* N.S.  N.S.                            
3,954,862                                                                 
        8    19459 mg.                                                    
                     N.I.   82.0*                                         
                               2.0* 16.0  N.I.                            
        8    2/19459 mg.                                                  
                     N.I.  95.0                                           
                               2.0    0.sup.(1)                           
                                          N.I.                            
U.S. Pat. No.                                                             
        1    9369 mg.                                                     
                     95.0  93.0                                           
                               2.0-3.0*                                   
                                    N.S.  93.0                            
4,001,321                                                                 
U.S. Pat. No.                                                             
        2    Less than                                                    
                     98.8  N.S.                                           
                               N.S. N.S.  99.7.sup.(2)                    
3,962,131    3332.4 mg..sup.(3)                                           
U.S. Pat. No.                                                             
        5    0.sup.(4)                                                    
                     75.2  98.0                                           
                               2.0  0     98.0                            
3,907,890                                                                 
Present 2    344.5 mg.                                                    
                     90.0  99.5                                           
                               0.45 Traces                                
                                          99.5                            
invention                                                                 
        4    620.6 mg.                                                    
                     99.1   99.89                                         
                               0    0     99.89                           
__________________________________________________________________________
 *values in the reaction mixture.                                         
 N.S. --not stated.                                                       
 N.I. --not isolated.                                                     
 .sup.(1) plus 3% of unknown substance.                                   
 .sup.(2) by U.V. method.                                                 
 .sup.(3) Rh content not stated: possible limit calculated from Example 1.
 .sup.(4) It does not use Rh but cobalt carbonyl.                         
 .sup.(5) .Iadd.(Combined first and second fractions).Iaddend..   results 
 obtained demonstrate the considerable improvement over the prior art
 processes.
Chloromethacycline, prepared according to U.S. Pat. No. 3,849,491, is an eminently suitable starting material in the present invention.
To perform the reaction, an 11a-halo-6-deoxy-6-demethyl-6-methylenetetracycline, preferably 11a-chloro-6-deoxy-6-demethyl-6-methylene-oxytetracycline p-toluenesulphonate, is suspended in methanol in a conventional low pressure stainless steel hydrogenation apparatus, then a tertiary phosphinehydrazino-chlororhodium catalyst and an additional amount of tertiary phosphine are added under stirring and hydrogenated subsequently at about 60° C. to 90° C. at a pressure between 4 and 10 kg/cm2 until the rate of consumption of hydrogen drops drastically. The reaction mixture is cooled down to about 45° C. and an excess of p-toluenesulphonic acid is added directly to the reaction mixture. It is allowed to cool down under stirring so as to reach a temperature of about 0° C. after 2 to 3 hours, then it is stirred for an additional hour, filtered and washed with methanol and acetone. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained has a purity superior to 99% and does not contain any detectable amount of the β-isomer by circular paper chromatography.
The amount of the additional tertiary phosphine to be added cannot surpass 1 mole/mole, otherwise the yield will drop drastically.
Table II gives a comparison of the present invention with the state of art in transforming 11a-chloro-6-deoxy-6-demethyl-6-methylene-5-oxytetracycline into α-6-deoxyoxytetracycline.
                                  TABLE II                                
__________________________________________________________________________
             Amount of rho-                                               
                     Stoichiome-                                          
             dium used per                                                
                     tric yield                                           
                           Content as    Purity of iso-                   
Patent       kg. 11a-chloro                                               
                     of isolated   Starting                               
                                         lated product                    
No.     Example                                                           
             MOT base                                                     
                     product %                                            
                           α-6%                                     
                               β-6%                                  
                                   material %                             
                                         %                                
__________________________________________________________________________
U.S. Pat. No.                                                             
         1   4889 mg 70.1  95.0*                                          
                               5.0*                                       
                                   Slight                                 
                                         98.9                             
3,962,331                          traces*                                
French Patent                                                             
         7   21752 mg                                                     
                     78.8  N.S.                                           
                               1.5-2*                                     
                                   N.S.  89.0                             
2216268 14   2159 mg 81.2  N.S.                                           
                               N.S.                                       
                                   N.S.   88.29                           
U.S. Pat. No.                                                             
        17   2140 mg 86.7  59.9                                           
                               1.33                                       
                                   0.8   59.9                             
3,954,862                      10                                         
Present 3A   346.1 mg                                                     
                     84.2  99.8                                           
                               0   0     99.8                             
invention                                                                 
        13   378.4 mg                                                     
                     90.7  99.6                                           
                               0.3 0     99.6                             
        16   224.6 mg                                                     
                     85.9  99.65                                          
                               0   Traces                                 
                                          99.65                           
__________________________________________________________________________
 *values in the reaction mixture.
The results clearly show the unexpected superiority of the new tertiary phosphine-hydrazino-chlororhodium complexes as hydrogenation catalysts not only concerning yields and purity but also in reducing the amount of rhodium necessary to complete the hydrogenation in relation to the prior art processes. The tertiary phosphine-hydrazino-chlororhodium complexes and their preparation as described in our co-pending patent application Ser. No. 458,068.
These new catalysts can be prepared either from a rhodium salt or from the already known tertiary phosphine rhodium complexes.
Thus, rhodium trichloride trihydrate (1 mole), a tertiary phosphine (1 to 2.5 moles) and an excess of hydrazine (up to 10 moles) are reacted, eventually by heating or refluxing them in a reaction inert solvent, such as a lower dialylketone, lower alcohol, tetrahydrofuran, dioxan or dimethylformamide, and the formed catalyst is then filtered off if it is insoluble in the reaction mixture or precipitated by adding a non-solvent, such as isopropylether, then filtered and dried.
Rhodium chloride trihydrate reacts with an excess of hydrazine hydrate, yielding a yellow compound which does not catalyse the hydrogenation of 6-methylene-oxytetracycline if triphenylphosphine is not added to the reaction mixture. In the presence of triphenylphosphine, however, a good quality α-6-deoxyoxytetracycline is obtained in high yield.
Alternatively, a tertiary phosphine rhodium complex (1 mole) can be reacted with an excess of hydrazine, substituted or not, the preferred catalyst being prepared by reacting tris(triphenylphosphine)chlororhodium (I) (1 mole) with an excess of hydrazine hydrate (3 moles) by stirring at room temperature in methanol. When the reaction mixture turns yellow, it is stirred for a few more minutes and it can be used either without isolation or it is filtered, washed and dried.
The following examples serve to illustrate the present invention, without in any way limiting the scope thereof.
EXAMPLE 1
Preparation of the catalyst: 0.48 ml of hydrazine hydrate was added to 3 g of tris(triphenylphosphine)chlororhodium in 60 ml of ethanol and refluxed for 25 minutes. The original dark red colour changed to orange during the reaction. Upon cooling, 1.4 g precipitated (N 4.25%; Rh 16.95%). From the mother liquors, additional amounts were obtained by adding isopropylether.
Hydrogenation: 25 mg of the thus obtained catalyts in 20 ml of methanol was added to a stainless steel hydrogenation apparatus under magnetic stirring, containing 7.38 g of 6-methylene-5-hydroxytetracycline hydrochloride (MOT HCl) and 0.1 g of triphenylphosphine in 40 ml of methanol. After purging it with nitrogen, hydrogen was added at a pressure of 8 kg/cm2 and heated up to 89° C. After 5 h 30 m the consumption dropped, and 1 hour later it was cooled down. The reaction mixture was filtered through a G4 glass-filter, then 3.3 g of p-toluenesulphonic acid was added to the filtrate and stirred. The α-6-deoxyoxytetracycline p-toluenesulphonate thus formed was filtered, washed with acetone and dried. The product, which weighed 9.65 g, had the following analytical values: humidity 3.13% by the Karl-Fisher method, yield 98.4% and purity 99.8% on anhydrous basis. No β-isomer or starting material were detectable by circular paper chromatography ("Schleicher Schull" paper Nr. 2045 B, 265 mm, ref. No. 381804; stationary phase: 100 ml of a solution of 0.1M citric acid and 40 ml of 0.2M anhydrous disodium phosphate were mixed to make a buffer with pH 3.5; mobile phase: nitromethane:chloroform:pyridine-20:10:3).
EXAMPLE 2
Example 1 was repeated but 15 mg of the catalyst was added instead of 25 mg. The α-6-deoxyoxytetracycline p-toluenesulphonate weighed 8.57 g. Yield 90%. It contained 0.45% of the β-isomer and traces of starting material.
EXAMPLE 3
(A) 15 mg of the triphenylphosphine-hydrazino-chlororhodium complex, obtained according to Example 1, was added in 20 ml of methanol to a stainless steel hydrogenator containing 10 g of 11a-chloro-6-deoxy-6-demethyl-6-methylene-5-hdyroxytetracycline p-toluenesulphonate and 4 g of triphenylphosphine in 40 ml of methanol. Then it was flushed with nitrogen and filled with hydrogen to a pressure of 9.2 kg/cm2 at 88° C. After 9 h 30 m, it was cooled down and the reaction mixture was filtered. 3.3 g of p-toluenesulphonic acid was added and stirred for 2 hours. The crystals thus formed were filtered and washed. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.0 g. Yield 84.2%. No β-isomer or starting material were detectable in the product by circular paper chromatography.
(B) Repetition of Example 3 (A) above with 10 mg of the same catalyst gave a yield of α-6-deoxyoxytetracycline p-toluenesulphonate of 7.82 g of 82.3%.
EXAMPLE 4
Preparation of the catalyst: It was performed as indicated in Example 1, however substituting ethanol by the same volume of n-butanol and stirring at room temperature for 20 minutes. The red colour turned orange during the reaction. Yield 1.43 g (N 6.21%, Rh 18.32%).
Hydrogenation: 25 mg of the catalyst thus obtained in 20 ml of methanol was added into a stainless steel hydrogenator containing 7.38 g of 6-methylene-5-hydroxytetracycline hydrochloride and 0.25 g triphenylphosphine in 40 ml of methanol. The hydrogenation and isolation were carried out as indicated in Example 1. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 9.95 g and had the following analytical values: loss on drying 5.32%, yield 99.14% and purity 99.89%, both on anhydrous basis. No β-isomer or starting material were detectable by circular paper chromatography.
EXAMPLE 5
Preparation of the catalyst: 0.16 ml of hydrazine hydrate was added to 1 g of tris(triphenylphosphine)chlororhodium in 20 ml of isopropanol and stirred at room temperature for 45 minutes. The precipitated catalyst was filtered and dried.
Hydrogenation: The hydrogenation procedure as described in Example 1 was repeated using 25 mg of the catalyst as obtained hereinabove. The α-6-deoxyoxytetracycline isolated as p-toluenesulphonate weighed 8.83 g and had the following analytical values: humidity 0.11% by Karl-Fisher, yield 92.82% and purity 99.9%, both on anhydrous basis.
EXAMPLE 6
25 mg of the catalyst as obtained in Example 5 in 20 ml of methanol was added to a stainless steel hydrogenator containing 7.38 g of 6-methylene-5-hydroxytetracycline hydrochloride in 40 ml of methanol. The hydrogenation and isolation were carried out as described in Example 1.
The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.17 g and had the following analytical values: humidity 2.18% by Karl-Fisher, yield 84.1% and purity 99.2%, both on anhydrous basis.
EXAMPLE 7
Preparation of the catalyst: 0.32 ml of phenylhydrazine was added to 1 g of tris(triphenylphosphine)chlororhodium in 20 ml of acetonitrile. It was heated to 65° C. for 25 minutes, whilst the product dissolved. The catalyst was precipitated by addition of isopropylether.
Hydrogenation: Example 1 was repeated using 25 mg of the catalyst obtained hereinabove. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.33 g. Yield 87.6%. It did not contain any starting material or β-isomer by circular paper chromatography.
EXAMPLE 8
Preparation of the catalyst: 1 g of rhodium trichloride trihydrate in 5 ml of water was stirred for 1 hour at 70° C. Subsequently, a solution of 1.95 g of triphenylphosphine in 25 ml of acetone was added to it in 20 minutes, followed by the addition of 1.9 ml of hydrazine hydrate. It was refluxed for 3 hours and then stirred for 1 hour at 45° C. It was then filtered and washed with acetone and diethylether.
Hydrogenation: 17 .[.ml.]. .Iadd.mg .Iaddend.of the catalyst hereinabove obtained in 13.5 ml of methanol was added to a stainless steel hydrogenator containing 5 g of 6-methylene-5-hydroxytetracycline hydrochloride in 27 ml of methanol. It was hydrogenated for 6 h 30 m at 88° C. at a pressure between 8 and 9.2 kg/cm2. 2.23 g of p-toluenesulphonic acid was added to the filtered reaction mixture and stirred for 2 hours. The crystals thus obtained were then filtered, washed with acetone and dried. The product weighed 5.4 g. Yield 83.9%. It contained slight traces of the β-isomer by circular paper chromatography. The mother liquors were then diluted with an equal volume of water and 4 g of sulphosalicylic acid was added. An additional 0.47 g of sulphosalicylate of doxycycline was obtained containing about 8% of the β-isomer and about 2% of decomposition product.
EXAMPLE 9
Example 8 was repeated but 68 mg of triphenylphosphine was also added to the reaction mixture prior to hydrogenation. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 5.36 g. Yield 83.3%. It contained traces of the β-isomer. The second crop as sulphosalicylate weighed 0.7 g and contained about 4% of the β-isomer.
EXAMPLE 10
Preparation of the catalyst: 0.5 g of rhodium trichloride trihydrate in 2.5 ml of water was heated for 1 hour at 70° C. under stirring and 0.8962 ml of hydrazine hydrate was added portionwise in 9.24 ml of acetone. After refluxing for 3 hours, it was cooled down and the crystals were filtered off.
Hydrogenation: The hydrogenation was carried out as described in Example 1 using 25 mg of the catalyst hereinabove prepared. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 7.96 g. Yield 83.8%. It contained about 1.5% of the β-isomer. The mother liquors were then diluted with an equal volume of water and 4 g of sulphosalicyclic acid was added. An additional 1.55 g of sulphosalicylate of doxycycline was obtained, which contained about 93% of the α-isomer and 7% of the β-isomer.
EXAMPLE 11
Example 10 was repeated but no triphenylphosphine was added to the hydrogenation reaction mixture. There was no consumption of hydrogen and the 6-methylene-5-hydroxytetracycline remained unchanged.
EXAMPLE 12
Preparation of the catalyst: 0.5 of rhodium trichloride trihydrate was heated for 1 hour at 70° C. in 2.5 ml of water. Subsequently, 0.98 g of triphenylphosphine was added in 12.5 ml of methylethylketone. It was stirred for 10 minutes and 3.37 g of benzenesulphonylhydrazine was added. It was heated to 67° C. during 3 hours under stirring and for an additional hour at 45° C. It was filtered, washed with methylethylketone and diethylether and dried.
Hydrogenation:
(A) 25 mg of the catalyst hereinabove obtained was used for repeating Example 1. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.57 g. Yield 90%. No β-isomer or starting material were detectable by circular paper chromatography.
(B) 25 mg of the above catalyst in 20 methanol was added to a stainless steel hydrogenator containing 10 g of 11a-chloro-6-deoxy-6-demethyl-6-methylene-5-hydroxytetracycline p-toluenesulphonate and 4 g of triphenylphosphine in 40 ml of methanol. It was flushed with nitrogen and filled with hydrogen to a pressure of 9 kg/cm2 at 88° C. After 6 h 30 m, the hydrogenator was cooled down and the reaction mixture was filtered. 3.3 g of p-toluenesulphonic acid was added to the filtrate and stirred for 2 hours. The crystals were filtered, washed with acetone and dried. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.27 g. Yield 87.0%. No β-isomer or starting material were detectable by circular paper chromatography.
EXAMPLE 13
Preparation of the catalyst: 8 μl of hydrazine hydrate was added to a suspension of 50 mg of tris(triphenylphosphine)chlororhodium in 10 ml of methanol and stirred at room temperature for a few minutes until a change of the colour of the reaction mixture occured.
Hydrogenation: the above catalyst was added without isolation to 20 g of 11a-chloro-6-deoxy-6-demethyl-6-methylene-5-hydroxytetracycline p-toluene sulphonate and 8 g of triphenylphosphine in 105 ml of methanol.
Subsequently, the above mixture was hydrogenated between 87° and 88.5° C. at a pressure of 8 kg/cm2 during 6 hours. The reaction mixture was then cooled down to about 45° C. and 6.7 g of p-toluenesulphonic acid was added under stirring. It was stirred for further 2 hours and cooled to 0° C. It was then filtered, washed with 2×5.5 ml of methanol and 2×5.5 ml of acetone and dried. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 17.23 g. Yield 90.7%. The content of β-isomer was 0.3% and no starting material was present by h.p.l.c. (Column: μ Bondapak "Waters" CN--ref. No. PN 84042 S/N; solvent: 80% of tetrahydrofuran, 20% of a mixture containing 80% of water, 20% acetic acid in 0.001M EDTA; flow rate: 2.5 ml/min.; detection: U.V. 268 nm; 1.0 AUFS; chart: 5 mm/min.).
EXAMPLE 14
Preparation of the catalyst: 0.08 ml of hydrazine hydrate was added to 0.5 g of tris(triphenylphosphine)chlororhodium in 10 ml of isopropanol and refluxed for 25 minutes. Then it was cooled down and filtered. The catalyst thus obtained 14.1% of rhodium.
Hydrogenation: Example 12 (B) was repeated using 25 mg of the triphenylphosphine-hydrazino-chlororhodium complex obtained hereinabove. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.02 g. Yield 84.4%. No β-isomer or starting material were detectable by circular paper chromatography.
EXAMPLE 15
Preparation of the catalyst: 0.5 g of rhodium trichloride trihydrate was heated to 70° C. for 1 hour in 2.5 ml of water under nitrogen atmosphere. Then 0.975 g of triphenylphosphine was added in 12.5 ml of methylethylketone, followed by 0.95 ml of hydrazine hydrate. After refluxing for 3 hours, followed by stirring at 45° C. during 1 hour, it was cooled and the crystals filtered, wahsed and dried.
Hydrogenation: Example 12 (B) was repeated using 25 mg of the catalyst obtained hereinabove. The α-6-deoxyoxytetracycline p-toluenesulphonate thus obtained weighed 8.04 g. Yield 84.6%. No β-isomer and no starting material were detectable by circular paper chromatography.
EXAMPLE 16
Preparation of the catalyst: 0.6 ml of a methanolic solution of hydrazine hydrate (0.394 ml/100 ml) was added under stirring to 15 mg of tris (triphenylphosphine)chlororhodium (Rh content 11.0%) in 20 ml of methanol and stirred for a few minutes until a colour change occurred.
Hydrogenation: The above reaction mixture of the catalyst was added to a stainless steel hydrogenator containing 10 g of 11a-chloro-6-deoxy-6-demethyl-6-methylene-5-hydroxytetracycline p-toluenesulphonate and 4 g of triphenylphosphine in 40 ml of methanol. It was flushed with nitrogen, then hydrogenated at a pressure of 9.2 kg/cm2 at 88° C. for 9 hours. It was then cooled down and filtered. Subsequently, 3.3 g of p-toluenesulphonic acid was added and the mixture stirred for 2 hours and filtered. The α-6-deoxyoxytetracycline p-toluenesulphonate thus formed weighed 8.16 g. Yield 85.9%. No β-isomer was detectable and slight traces of starting material were present in circular paper chromatography.

Claims (20)

We claim:
1. A new improved homogeneous hydrogenation process to prepare α-6-deoxytetracyclines in high yield and purity from a 6-deoxy-6-demethyl-6-methylenetetracycline or salt thereof in the presence or absence of a tertiary phosphine or from a 11a-chloro-6-deoxy-6-demethyl-6-methylenetetracycline or a salt thereof in the presence of a tertiary phosphine by catalytic hydrogenation, characterised in that the catalyst is a tertiary phosphine-hydrazino-chlororhodium obtained by reacting a rhodium salt or a complex with a hydrazine or salt thereof.
2. Process according to claim 1, wherein for each part of substrate to be hydrogenated the amount of rhodium metal in the catalyst necessary to perform the hydrogenation is less than 0.0007 part.
3. Process according to claim 1 wherein the rhodium salt or complex is tris(triphenylphosphine)chlororhodium and the hydrazine or a salt thereof is hydrazine.
4. Process according to claim 1 wherein the rhodium salt or complex is tris(triphenylphosphine)chlororhodium and the hydrazine or salt thereof is phenyl hydrazine.
5. Process according to claim 1 wherein the rhodium salt or complex there of is rhodium trichloride trihydrate and the hydrazine or salt thereof is hydrazine.
6. Process according to claim 1 wherein the catalyst is the reaction product of rhodium trichloride trihydrate, triphenylphosphine and benzenesulphonylhydrazine.
7. Process according to claim 1 wherein 6-deoxy-6-demethyl-6-methylene-tetracycline or salt thereof is hydrogenated in the presence of said catalyst and 0.01-0.06 mole of tertiary phosphine per mole of .[.tertiary phosphine of said catalyst.]. .Iadd.compound hydrogenated.Iaddend..
8. Process according to claim 7 wherein the tertiary phosphine in the catalyst and the additional tertiary phosphine in which the reaction is carried out in the presence of are the same.
9. Process according to claim 1 in which a 11a-chloro-6-deoxy-6-demethyl-6-methylenetetracycline or a salt thereof is hydrogenated in the presence of said catalyst and up to 1 mole of tertiary phosphine per mole of .[.tertiary phosphine in said catalyst.]. .Iadd.compound hydrogenated.Iaddend..
10. Process according to claim 9 wherein the tertiary phosphine in the catalyst and the additional tertiary phosphine in which the reaction is carried out in the presence of are the same.
11. Process according to claim 1 wherein 6-deoxy-6-demethyl-6-methylenetetracycline or salt thereof is hydrogenated.
12. Process according to claim 1 wherein the pure α-6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
13. Process according to claim 2, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
14. Process according to claim 3, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesolufonate by addition of an excess of p-toluenesulfonic acid.
15. Process according to claim 4, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
16. Process according to claim 5, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
17. Process according to claim 6, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
18. Process according to claim 7, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
19. Process according to claim 8, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
20. Process according to claim 9, wherein the pure α6-deoxytetracycline formed is recovered directly from the reaction mixture as crystalline p-toluenesulfonate by addition of an excess of p-toluenesulfonic acid.
US06/858,660 1982-01-19 1986-05-01 Process for the preparation of α-6-deoxytetracyclines Expired - Lifetime USRE32535E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US06/858,660 USRE32535E (en) 1982-01-19 1986-05-01 Process for the preparation of α-6-deoxytetracyclines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT198274303A PT74303B (en) 1982-01-19 1982-01-19 PROCESS FOR THE PREPARATION OF NEW CATALYZERS CONTAINING RHODIUM AND USE THEREOF
PT198276061A PT76061A (en) 1982-12-30 1982-12-30 Stable homogeneous hydrogenation rhodium catalyst - useful in high yield prodn. of doxycycline by stereospecific hydrogenation
US06/858,660 USRE32535E (en) 1982-01-19 1986-05-01 Process for the preparation of α-6-deoxytetracyclines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/458,067 Reissue US4500458A (en) 1982-01-19 1983-01-14 Process for the preparation of α-6-deoxytetracyclines

Publications (1)

Publication Number Publication Date
USRE32535E true USRE32535E (en) 1987-10-27

Family

ID=27354096

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/858,660 Expired - Lifetime USRE32535E (en) 1982-01-19 1986-05-01 Process for the preparation of α-6-deoxytetracyclines

Country Status (1)

Country Link
US (1) USRE32535E (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857235A (en) 1982-12-30 1989-08-15 Plurichemie Anstalt Process of preparation of novel rhodium hydrogenation catalysts and their application
US4902447A (en) 1988-10-28 1990-02-20 Ranbaxy Laboratories Limited Process for the production of alpha-6-deoxytetracyclines and hydrogenation catalyst useful therein
US4987242A (en) * 1988-10-28 1991-01-22 Jagmohan Khanna Hydrogenation catalyst useful in the production of alpha-6-deoxytetracyclines
US5075470A (en) * 1989-07-31 1991-12-24 Plurichemie Anstalt Process for the preparation of a rhodium complex
US20060183719A1 (en) * 2005-01-21 2006-08-17 Devries Tina M Tetracycline metal complex in a solid dosage form
US7485319B2 (en) 2003-07-25 2009-02-03 Warner Chilcott Company, Inc. Doxycycline metal complex in a solid dosage form

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA668581A (en) * 1963-08-13 R. D. Mccormick Jerry Process for the catalytic reduction of 6-hydroxy hydronaphthacenes
NL7401340A (en) * 1973-02-01 1974-08-05
US3849491A (en) * 1970-07-03 1974-11-19 I Villax Process of dehalogenation and dehalogenation with simultaneous reduction of 11a-halo-6-deoxy-6-demethyl-6-methylenetetracyclines by hydrazine
US3954862A (en) * 1973-04-20 1976-05-04 Pfizer Inc. Process for producing α-6-deoxytetracyclines
GB1440372A (en) * 1973-02-01 1976-06-23 Pfizer Process for the preparation of tetracyclines
US4001321A (en) * 1975-06-26 1977-01-04 Pfizer Inc. Preparation of α-6-deoxytetracyclines
US4031137A (en) * 1975-03-19 1977-06-21 American Cyanamid Company Catalysts based on carbon supports and use in catalytic deoxidation process
US4207258A (en) * 1972-02-24 1980-06-10 Ankerfarm S.P.A. Process for the preparatin of α-6-deoxytetracyclines

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA668581A (en) * 1963-08-13 R. D. Mccormick Jerry Process for the catalytic reduction of 6-hydroxy hydronaphthacenes
US3849491A (en) * 1970-07-03 1974-11-19 I Villax Process of dehalogenation and dehalogenation with simultaneous reduction of 11a-halo-6-deoxy-6-demethyl-6-methylenetetracyclines by hydrazine
US4207258A (en) * 1972-02-24 1980-06-10 Ankerfarm S.P.A. Process for the preparatin of α-6-deoxytetracyclines
NL7401340A (en) * 1973-02-01 1974-08-05
FR2216268A1 (en) * 1973-02-01 1974-08-30 Pfizer Catalytic hydrogenation of 6-methylenetetracyclines - using rhodium-tert phosphine complex catalyst giving a stereospecific prod. in high yield
GB1440372A (en) * 1973-02-01 1976-06-23 Pfizer Process for the preparation of tetracyclines
US3954862A (en) * 1973-04-20 1976-05-04 Pfizer Inc. Process for producing α-6-deoxytetracyclines
US4031137A (en) * 1975-03-19 1977-06-21 American Cyanamid Company Catalysts based on carbon supports and use in catalytic deoxidation process
US4001321A (en) * 1975-06-26 1977-01-04 Pfizer Inc. Preparation of α-6-deoxytetracyclines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
U.S. Ser. No. 328,514 filed Feb. 1, 1973, Priority Document for France No. 2,216,268. *
U.S. Ser. No. 368,066 filed Jun. 8, 1973, Priority Document for France No. 2,216,268. *
U.S. Ser. No. 428,268 filed Dec. 6, 1973, Priority Document for France No. 2,216,268. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857235A (en) 1982-12-30 1989-08-15 Plurichemie Anstalt Process of preparation of novel rhodium hydrogenation catalysts and their application
US4902447A (en) 1988-10-28 1990-02-20 Ranbaxy Laboratories Limited Process for the production of alpha-6-deoxytetracyclines and hydrogenation catalyst useful therein
US4987242A (en) * 1988-10-28 1991-01-22 Jagmohan Khanna Hydrogenation catalyst useful in the production of alpha-6-deoxytetracyclines
US5075470A (en) * 1989-07-31 1991-12-24 Plurichemie Anstalt Process for the preparation of a rhodium complex
US7485319B2 (en) 2003-07-25 2009-02-03 Warner Chilcott Company, Inc. Doxycycline metal complex in a solid dosage form
US20110171299A1 (en) * 2003-07-25 2011-07-14 Warner Chilcott Company, Inc. Doxycycline metal complex in a solid dosage form
US8415331B2 (en) 2003-07-25 2013-04-09 Warner Chilcott Company, Llc Doxycycline metal complex in a solid dosage form
US20060183719A1 (en) * 2005-01-21 2006-08-17 Devries Tina M Tetracycline metal complex in a solid dosage form

Similar Documents

Publication Publication Date Title
US4500458A (en) Process for the preparation of α-6-deoxytetracyclines
US4597904A (en) Process for the preparation of α-6-deoxy-tetracyclines
US4877559A (en) New process for the preparation of alpha-6-deoxy-5-hydroxytetracycline
USRE32535E (en) Process for the preparation of α-6-deoxytetracyclines
US4207258A (en) Process for the preparatin of α-6-deoxytetracyclines
US3954862A (en) Process for producing α-6-deoxytetracyclines
CA1218058A (en) Process for the preparation of new rhodium-containing catalysts and their application
US4290961A (en) Process for catalytically reducing carbonyl compounds
IE41554B1 (en) Preperation of 6-deoxy-5-hydroxytetracycline
US3962331A (en) Process for the preparation of α-6-deoxytetracyclines
US4987242A (en) Hydrogenation catalyst useful in the production of alpha-6-deoxytetracyclines
JPS6251946B2 (en)
WO1998038201A1 (en) Process for the preparation of ivermectin
JPS6114145B2 (en)
Kobayashi et al. Cobalt-mediated Reduction of C= N Bond. Synthesis of Methyl N-p-Toluenesulfonyl-1-phenylglycinate Catalyzed by Bis (dioximato) cobalt–Quinine Complexes
US4863639A (en) Application of catalysts containing rhodium
EP0366565A2 (en) Process for the production of alpha-6-deoxytetracyclines and hydrogenation catalyst useful therein
US4973719A (en) Process for the production of alpha-6-deoxytetracyclines
US4990636A (en) Process for the production of alpha-6-deoxytetracyclines and hydrogenation catalyst useful therein
AU595606B2 (en) Process of preparation of new catalysts containing rhodium and their application
US4997959A (en) Process for the production of alpha-6-deoxytetracyclines
KR790001339B1 (en) Prozess for producing -6-deoxytertraclines
US4550181A (en) Process for preparing gamma-caprolactone from polycaprolactone
EP1185501B1 (en) Preparation of substituted aromatic amines
IE900005A1 (en) Process for the production of alpha-6-deoxytetracyclines and¹hydrogenation catalyst useful therein

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12